Bull Case

ZORYVE demand continues to scale across plaque psoriasis and atopic dermatitis, driving revenue growth well above peers with limited commercial dilution.

Label expansion and broader payer access improve persistence and refill rates, lifting gross profit leverage faster than dermatology peers.

Operating leverage from a larger installed base expands margins from the current low-single-digit level, narrowing the gap versus profitable specialty peers.

Moderate leverage remains manageable as EBITDA grows, reducing financing pressure and supporting continued investment without materially constraining growth.

Base Case

ZORYVE remains the primary growth engine, but adoption normalizes after launch momentum, producing steady revenue growth that still outpaces many dermatology peers.

Payer coverage and physician uptake improve gradually, supporting continued share gains while commercialization costs keep operating margins positive but modest.

Margin expansion is incremental rather than step-change, as Arcutis converts scale into earnings more slowly than larger, diversified dermatology peers.

Leverage stays serviceable at current levels, but interest expense and valuation expectations limit flexibility versus stronger balance-sheet peers.

Bear Case

ZORYVE uptake slows if payer friction or competitive promotion intensifies, causing revenue growth to decelerate toward peer-like levels.

Commercial spending stays elevated to defend share, preventing margin expansion and leaving operating profitability below better-capitalized dermatology peers.

Higher-than-expected cash burn or refinancing needs pressure the balance sheet, increasing dilution or financing risk relative to peers with stronger cash generation.

If launch execution weakens, the company loses its growth premium and valuation compresses toward lower-growth specialty pharma comparables.

Overall Score

ARQT’s forward profile is anchored by ZORYVE-led growth and improving scale economics, with leverage and execution risk preventing a higher overall score.